LL-37 Complex (5mg)

Broad-Spectrum Antimicrobial Action:

LL‑37 disrupts microbial membranes and exhibits potent activity against bacteria, fungi, and viruses in vitro [2][6]. 

Immunomodulatory Regulation:

LL‑37 interacts with immune receptors like FPRL‑1 and P2X7, influencing chemotaxis, cytokine production, innate immunity, and interferon responses [3][7]. 

Biofilm Disruption & Resistance Potential:

It prevents biofilm formation and disassembles existing biofilms, making it a promising molecule in antimicrobial research targeting resistant organisms [2][6]. 

Peptide Self‑Assembly:

A core segment (residues 17–29) self-assembles into helical peptide fibrils, retaining antibacterial activity and suggesting functional structural organization in bioactive states [5]. 

Citations

1. RCSB PDB – Structure of LL‑37 in lipid micelles (NMR, PDB ID 2K6O); demonstrates amphipathic α-helix in membrane context. 
2. MDPI Biomolecules 2024;14(3):320. “LL‑37: antimicrobial activity, immune modulation, biofilm inhibition.” 
3. Springer Immunomodulatory Antimicrobial Peptide LL‑37 (2020). Overview of LL‑37’s immune-regulatory roles. 
4. Biochemistry (2006); 26: Structure of LL‑37 and its interaction with membranes via NMR. 
5. Nature Communications 2020;11:3894. “LL‑37(17–29) forms antimicrobial helical fibrils.” 
6. Antibiotics 2021;10(6):650. “LL‑37: antimicrobial and anti-biofilm agent with resistance-combat potential.” 
7. FASEB Journal 2006;20:2068–2080. “LL‑37 activates FPRL‑1 and P2X7 receptors— modulates chemotaxis and cytokine responses.”